Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jaguar Health Inc (NQ: JAGX ) 1.170 -0.060 (-4.88%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 221,618 Open 1.230 Bid (Size) 1.180 (5) Ask (Size) 1.210 (10) Prev. Close 1.230 Today's Range 1.160 - 1.230 52wk Range 0.9501 - 31.74 Shares Outstanding 171,350,166 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award August 20, 2024 Via ACCESSWIRE Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) August 19, 2024 Via ACCESSWIRE Performance YTD -87.10% -87.10% 1 Month -13.33% -13.33% 3 Month -70.97% -70.97% 6 Month -67.50% -67.50% 1 Year -95.12% -95.12% More News Read More JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024 August 13, 2024 Via InvestorPlace Why Jaguar Health (JAGX) Stock Is Down 15% August 13, 2024 Via Benzinga Jaguar Health Reports Second Quarter 2024 Financial Results August 13, 2024 Via ACCESSWIRE REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients August 12, 2024 Via ACCESSWIRE Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) July 31, 2024 Via ACCESSWIRE Why Jaguar Health Stock Is Crashing July 23, 2024 Via Benzinga Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement June 26, 2024 Via ACCESSWIRE Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders June 21, 2024 Via ACCESSWIRE Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful August 05, 2024 Via ACCESSWIRE Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy August 02, 2024 Via ACCESSWIRE Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting August 01, 2024 Via ACCESSWIRE Gold Moves Higher; Coca-Cola Increases FY24 Forecast July 23, 2024 Via Benzinga Why Is Azitra (AZTR) Stock Up 315% Today? July 23, 2024 Via InvestorPlace Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session July 23, 2024 Via Benzinga Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading July 23, 2024 Via InvestorPlace Topics ETFs Why Is Serve Robotics (SERV) Stock Down Today? July 23, 2024 Via InvestorPlace Why Is Jaguar Health (JAGX) Stock Down 55% Today? July 23, 2024 Via InvestorPlace Crude Oil Down 2%; GE Aerospace Earnings Top Views July 23, 2024 Via Benzinga Exposures Fossil Fuels US Stocks Edge Higher; General Motors Posts Upbeat Earnings July 23, 2024 Via Benzinga Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer July 23, 2024 Via ACCESSWIRE Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning July 18, 2024 Via ACCESSWIRE Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs) July 08, 2024 Via ACCESSWIRE Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 June 12, 2024 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.